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Given the complex nature of Alzheimer’s disease
(AD), a cell-based model that recapitulates the phys-
iological properties of the target neuronal pop-
ulation would be extremely valuable for discovering
improved drug candidates and chemical probes to
uncover disease mechanisms. We established
phenotypic neuronal assays for the biogenesis and
synaptic action of amyloid b peptide (Ab) based on
embryonic stem cell-derived neurons (ESNs). ESNs
enriched with pyramidal neurons were robust,
scalable, and amenable to a small-molecule
screening assay, overcoming the apparent limita-
tions of neuronal models derived from human plurip-
otent cells. Small-molecule screening of clinical
compounds identified four compounds capable of
reducing Ab levels in ESNs derived from the
Tg2576 mouse model of AD. Our approach is there-
fore highly suitable for phenotypic screening in AD
drug discovery and has the potential to identify ther-
apeutic candidates with improved efficacy and
safety potential.
INTRODUCTION
The elevation and accumulation of amyloid b peptide (Ab) in the
brain are early and necessary steps in the pathogenesis of
Alzheimer’s disease (AD), preceding all known clinical and path-
ological phenotypes of the disease, including memory and
cognitive decline, by at least a decade (Hardy and Selkoe,
2002; O’Brien and Wong, 2011; Zheng and Koo, 2011). Ab is
liberated from b-amyloid precursor protein (APP) by the mem-
brane-bound proteases b-secretase (BACE1) and g-secretase
(Hardy and Selkoe, 2002; O’Brien and Wong, 2011; Zheng and
Koo, 2011). To date, the majority of therapeutic strategies have
focused on the development of potent small-molecule inhibitors
to target well-defined enzymatic targets, including secretase en-
zymes. Despite their initial promise, however, most of these ap-956 Chemistry & Biology 20, 956–967, July 25, 2013 ª2013 Elsevier Lproaches have suffered major setbacks in late-stage clinical tri-
als (Mangialasche et al., 2010). Therefore, model systems and
biomarkers that can better predict the efficacy and safety of ther-
apeutic candidates in human clinical trials have become increas-
ingly important.
Cell types historically used in AD drug discovery, such as
immortalized or genetically transformed neuronal lines, lack the
complete phenotypic properties of primary neurons. Although
dissociated primary neuronal cultures are a better physiological
model compared with cell lines, they have major limitations due
to short survival times in culture, cellular heterogeneity, and
inability for large-scale production (McNeish, 2004; Pouton and
Haynes, 2007). Stem cell technology furnishes a novel opportu-
nity for generating a physiologically relevant diseasemodel using
directed differentiation of stem cells into an optimal cell type for
functional studies and drug discovery (McNeish, 2004; Pouton
and Haynes, 2007; Rubin and Haston, 2011).
A human neuronal model derived from human embryonic stem
cells (hESCs) or patient-derived induced pluripotent stem cells
(hiPSCs) would ultimately serve as the ideal disease model,
and eventually would be able to predict drug responsiveness in
cells originating from the patient’s own tissue (Jang et al.,
2012; Yamanaka and Blau, 2010). However, despite their great
promise, the productive and reliable use of hESCs or hiPSCs in
drug discovery remains challenging (Ebert and Svendsen,
2010; Han et al., 2011). For drug screening applications such
as high-throughput screening (HTS), hESC and hiPSC protocols
require laborious maintenance, which makes automation and
differentiation into functional neurons challenging (Ebert and
Svendsen, 2010). Furthermore, genetic and epigenetic variability
among patients may influence pharmacological responsiveness,
hindering the practical application of stem cells from human
patient origin for drug discovery (Han et al., 2011). In comparison
with human stem cells, mouse ESCs (mESCs) have several
notable advantages for bioassays and drug-discovery app-
lications, including the relatively homogeneous nature of differ-
entiated cells, potential derivation from disease models, and
convenient expandability (Pouton and Haynes, 2007). It has
been shown that mESCs can be differentiated into specific
neuronal subtype(s), including pyramidal neurons, a significantly
vulnerable neuronal population in AD (Mann, 1996; Morrison and
Hof, 2002).td All rights reserved
Figure 1. Directed Differentiation of mESCs into Pyramidal Cell-Enriched Neurons
(A) Schematic of the differentiation procedure for ESNs using primary MEFs (pMEFs) and retinotic acid (RA), showing ESCs and ESNs at DIV 5.
(B) ESC-derived neuronal culture at DIV 7 colabeled with neuronal b-tubulin III (TUJ1) and EMX1 antibodies, and DAPI to identify nuclei.
(C) ESC-derived neuronal culture at DIV 7 costained with GFAP and TUJ1 antibodies, and DAPI to identify nuclei.
(D) Quantification of cultures shows that only 6(±1.5)% of cells stained positive for GFAP, whereas 68(±10)% of cells were positive for EMX1 and 89.5(±4)% of
cells were positive for TUJ1. Scale bar represents 40 mm.
(E) Cultures increasingly express neuronal proteins, as assessed by western analysis using the indicated antibodies.
(F) Confocal images of DIV 21 neurons derived from mESCs detect the postsynaptic density protein PSD-95 and presynaptic density protein S-physin, which
localize to adjacent puncta at higher magnification (lower panel).
(G) Electron micrograph showing intact synaptic structures, including postsynaptic density and presynaptic vesicles, in DIV 21 cultures.
(H) PSD-95 and S-physin detection by western analysis in ESCs, ESN at specified DIV, and primary hippocampal neurons (PHN).
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Alzheimer’s Disease Neuronal Model from Stem CellsTo establish an AD-centric primary neuronal model, we devel-
oped phenotypic-cell-based assays for the biogenesis and syn-
aptic action of Ab using mESC-derived neuronal cultures en-
riched in functional pyramidal neurons. We isolated ESCs from
a mouse model of the disease, Tg2576, which harbors human
APP with the Swedish mutation (APPsw). To validate the applica-
tion of mESC-derived neurons (ESNs), we screened a library of
clinical compounds and identified four compounds capable of
reducing Ab levels. Our neuronal model is therefore highly suit-
able for phenotypic screening in AD drug discovery and has the
potential to enhance the predictive value of cell-based screeningChemistry & Biology 20,assays for lead compounds with a higher probability of surviving
advanced rounds of vetting for efficacy and diminished toxicity.
RESULTS
Characterization of Pyramidal Cell-Enriched ESN
Cultures
We produced a neuronal culture that was highly enriched in py-
ramidal neurons by directed differentiation of mESCs according
to published protocols with certain modifications (Figure 1A; Bi-
bel et al., 2004, 2007). Neuronal morphology was apparent after956–967, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 957
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Alzheimer’s Disease Neuronal Model from Stem Cells1 day in vitro (DIV) and the majority of cells displayed neuronal
morphology by DIV 5 (Figure 1A). By DIV 7, neuronal proteins,
including neuronal b-tubulin III (TUJ1) and pyramidal neuron
marker EMX1, were expressed, indicating a highly homo-
geneous neuronal population enriched in pyramidal neurons
(Figures 1B and 1D; Chan et al., 2001). Glial cells, identified by
glial fibrillary acidic protein (GFAP), were only rarely observed
(Figures 1C and 1D). Neuron-specific proteins (TUJ1 and syn-
aptophysin [S-physin]) and glutamatergic neuronal proteins
(TrkB and CaMKIIa) increased from DIV 1 to DIV 7, and there
was a gradual decline in the levels of the p75 neurotrophin recep-
tor (p75NTR) consistent with maturing pyramidal neurons
(Figure 1E; Buck et al., 1988). The subcellular distribution of
endogenous presynaptic S-physin and postsynaptic density
protein (PSD-95) as adjacent puncta along dendrites recapitu-
lated mature synapses in primary neurons (Figure 1F). Electron
microscopy analysis revealed that both presynaptic vesicles
and postsynaptic densities were apparent in this culture (Fig-
ure 1G). Expression of PSD-95 and S-physin was evident by
western analysis by DIV 14 (Figure 1H) but not in ESCs.
Modeling Ab-Induced Synaptic Alterations in ESNs
Oligomeric Ab induces both structural and functional alterations
at synapses in cultured neurons (Pozueta et al., 2012). To model
this usingmouse ESNs, we examined the effects of Ab treatment
on synaptic morphology and changes in cell-signaling events
indicative of synaptic plasticity. Synapse loss is documented in
AD mouse models and after treatment of neurons with oligo-
meric Ab, correlating with the loss of immunoreactivity of PSD-
95, a postsynaptic protein (Cerpa et al., 2010; Gylys et al.,
2004; Roselli et al., 2005). In ESNs, oligomeric Ab treatment
decreased the PSD-95 puncta count, fractional area, and total
area, but S-physin puncta, a presynaptic protein, remained un-
changed (Figures 2A–2F; Hu, et al., 2003; King and Arendash,
2002; Jacobsen et al. ,2006). Ab treatment also triggers morpho-
logical defects in synaptic spines, including a reduction in den-
dritic spine density (Hsieh et al., 2006; Shankar et al., 2007; Lacor
et al. ,2007). DiOlistic labeling of neurons (Moolman et al., 2004;
McIntire et al., 2012) revealed that treatment of ESNs with Ab
oligomers reduced spine density (Figures 2G and 2H). After Ab
oligomer treatment, the spine length increased modestly and
the dendritic diameter decreased slightly (Figures 2I and 2J; Cal-
abrese et al., 2007; Lacor et al., 2007). In addition to morpholog-
ical spine changes, at a functional level, Ab has been shown to
induce characteristic molecular changes in neurons, including
suppressed phosphorylation of cyclic AMP response element
binding protein (CREB), a memory-associated transcription fac-
tor (Vitolo et al., 2002; Snyder et al., 2005). In ESNs, Ab oligomer
treatment prevented NMDA-stimulation-dependent phosphory-
lation of CREB (pCREB; Figures 2K and 2L). Treatment of
ESNs with Ab oligomer at high concentrations led to neuronal
death (Figure S1 available online).
Expression of Secretase Components in ESNs
To determine whether the ESNs would effectively model Ab
biogenesis, we determined the expression of enzymatic compo-
nents of APP processing. ESNs express the b-site APP cleaving
enzyme (BACE1) at later stages of differentiation, but it is not
expressed in ESCs (Figures 3A and 3C; O’Brien and Wong,958 Chemistry & Biology 20, 956–967, July 25, 2013 ª2013 Elsevier L2011; Zheng and Koo, 2011). In contrast, presenilin 1 (PS1)
was detected in mESCs, consistent with its described role in
development (Figure 3B; Wong et al., 1997). Further, APP and
BACE1 were enriched in the late endosomal compartment en-
riched for syn6 and rab11, and de-enriched in early endosomes
containing early endosomal protein A1 (EEA1), consistent with
reported distributions in cultured primary neurons (Figure 3C;
Tang, 2009; Finan et al., 2011; Wen et al., 2011).
Genetic Modeling of the Expression of Familial AD-
Associated APP and PS1 in ESNs
To model familial AD (FAD), we infected wild-type ESNs
with APPsw lentivirus and analyzed APP processing. Treatment
of infected ESNs with BACE1 inhibitor (BSI) (Stachel et al.,
2006) reduced the secretion of secreted APPb-cleaved frag-
ment (sAPPb), Ab40, and Ab42, whereas treatment with g-sec-
retase inhibitor (GSI) (Seiffert et al., 2000) inhibited Ab40 and
Ab42 secretion without affecting the levels of sAPPb or sAPPa
(Figures 3D and 3F). Consistent with previous studies in cell
models and mouse brain, C-terminal fragments (CTFs) resulting
from APP cleavage accumulated in response to GSI treatment
(Figure 3D; Hardy and Selkoe, 2002; Landman et al., 2006;
O’Brien and Wong, 2011; Okada et al., 2010; Zheng and Koo,
2011).
Mutations in the genes encoding PS1 are the most common
cause of early-onset FAD (Hardy and Selkoe, 2002; O’Brien
and Wong, 2011; Zheng and Koo, 2011). To model PS1-linked
FAD phenotypes in ESNs, three different FAD mutant PS1 trans-
genes (DE9, M146V, and L286V) were electroporated into
mESCs to produce ESC lines stably expressing the mutants.
The resulting stable mESCs were subjected to directed differen-
tiation into pyramidal neurons. A representative western blot
shows the PS1 transgene and normal neuronal protein expres-
sion in ESNs derived from these clonal mESC lines (Figures 3G
and 3H). An increase in the Ab42/Ab40 ratio, a key pathogenic
phenotype associated with PS1 FAD (O’Brien and Wong, 2011;
Zheng and Koo, 2011), was observed in ESNs expressing DE9
M146V, and L286V mutant forms of PS1 after APPsw lentiviral
infection (Figure 3I).
ESNs from the Tg2576 Mouse Model of AD
In order to achieve robust and reproducible neuronal expression
of human APP, we isolated mESCs from the inner cell mass of
blastocysts from a well-characterized mouse model of AD,
Tg2576 (Hsiao et al., 1996). ESNs from Tg2576 showed normal
neuronal differentiation by morphology and neuronal protein
expression (Figures 4A and 4B), comparable to neuronal differ-
entiation of wild-type ESCs. Transgene-derived human APPsw
was expressed at DIVs 1–7, but little expression was detected
in the undifferentiated mESCs (Figure 4B). APP processing at
DIV 7 was sensitive to BSI, GSI, and an a-secretase inhibitor,
TAPI-2. APP CTF expression increased in response to GSI treat-
ment, but the levels of the neuronal proteins S-physin, CaMKIIa,
and neuronal b-tubulin did not change with any pharmacological
treatment (Figure 4C). Soluble sAPPa and sAPPb were reduced
by TAPI-2 and BSI treatment, respectively (Figure 4D). Further,
human Ab40 and Ab42 were reduced by treatment of neurons
with BSI and GSI as predicted (Figures 4E and 4F; Seiffert
et al., 2000; Stachel et al., 2006).td All rights reserved
Figure 2. Modeling Ab-Associated Synaptic Abnormalities in ESNs
(A and B) At DIV 21, ESNs were treated for 24 hr with DMSO control (Ctrl) or Ab42 oligomer, and subsequently fixed and costained for synaptic proteins PSD-95
(green) and S-physin (red). Nuclei are labeled with DAPI (blue). PSD-95 and S-physin particles were analyzed using ImageJ software.
(C–F) Quantification of PSD-95-positive particles and S-physin-positive particles using ImageJ software particle analysis.
(G) DIV 21 ESNs were treated with control or Ab42 oligomer, fixed, diOlistically labeled, and imaged with confocal microscopy.
(H–J) Dendrite diameter and spine density and length were quantified using ImageJ software.
(K) Phosphorylation of CREB was detected with a pCREB-specific antibody after no stimulation (NS) or NMDA stimulation (ST) of cultures with or without Ab42
oligomer (Ab) treatment.
(L) Quantification of CREB and pCREB using an infrared quantitative western blot imaging system. Error bars show SEM (n = 4).
See also Figure S1.
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HTS using a miniaturized assay allows for rapid and parallel ex-
amination of the bioactivities of large numbers of compounds. ToChemistry & Biology 20,accommodate HTS in ESNs, we miniaturized an Ab detection
assay using Tg2576 ESNs cultured in a 96-well plate. We deter-
mined the optimal cell density and assay parameters to optimize956–967, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 959
Figure 3. ESNs Harbor Machinery for APP Processing and Recapitulate a Phenotype Associated with PS1 FAD
(A) APP and BACE1 expression in mESCs and ESNs at DIVs 7, 14, and 21.
(B) Components of g-secretase (PS1, APH-1, NCT, and PEN2) were detected by western blot analysis of the cell lysates using the indicated antibodies.
(C) Gradient centrifugation shows that APP and BACE1 are enriched in the late endosome compartment with Syn6 and Rab11, but not at the top of the gradient
with EEA1.
(D) Western blot analysis of protein lysates from ESNs infected with lentivirus harboring human APPsw expressing APP and proteolytic fragments. Secreted APP
fragments (sAPPb and sAPPa) were immunoprecipitated from conditioned media, and APP and CTFs were detected in cell lysates.
(E and F) Ab40 and Ab42 were detected in conditioned medium using human-specific ELISA, and values were normalized to protein lysate concentration.
(G) Three different FADmutants of PS1 (DE9,M146V, and L286V) were introduced intomESCs, whichwere subsequently subjected to directed differentiation into
pyramidal neurons. A representative western blot shows transgene expression in the neurons derived from these clonal mESC lines using an anti-human PS1-
specific antibodies (PS1-NT and PS1-loop).
(H) PS FAD-expressing cells undergo normal directed differentiation into pyramidal neurons, as indicated by expression of neuronal proteins.
(I) ELISA detection of Ab42 and Ab40 from conditioned media of ESNs stably expressing PS-FAD mutants infected at DIV 7 or 14 with APPsw lentiviral particles
resulted in an enhanced ratio of Ab42/Ab40. Lentiviral gene transfer did not affect the viability of ESNs (data not shown).
See also Figure S2.
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density of 1.5 3 105 cells/cm2 maximized the cell viability signal
(Figures 5A and 5C). Two parameters that are commonly used to
evaluate the robustness of a HTS assay are the coefficient of
variance (%CV) and Z0 factor (Inglese et al., 2007). Typically, an
assay with %CV value < 15% and Z0 factor > 0.5 is considered
a robust assay suitable for HTS (Inglese et al., 2007). At the
plating density of 1.5 3 105 cells/cm2, with five replicate wells,960 Chemistry & Biology 20, 956–967, July 25, 2013 ª2013 Elsevier Lboth the %CV (Figure 5B) and Z0 factor (Figure 5C) were opti-
mized. When the optimized 96-well platform was used, ESNs
derived from the Tg2576 mouse model displayed characteristic
inhibitor-response kinetic profiles for both BSI and GSI (Figures
4E and 4F; Seiffert, et al., 2000; Stachel et al., 2006). Values of %
CV for Ab40 and Ab42 indicated acceptable variance for signal
detection (Inglese et al., 2007). Additional metrics, including
the signal/noise ratio, signal/background ratio, and signaltd All rights reserved
Figure 4. Analysis of mESCs and ESNs Isolated from the Tg2576 AD Mouse Model
(A) Tg2576 ESNs identified by nuclear DAPI stain express neuronal b-tubulin III (TUJ1; green) and pyramidal cell protein (EMX1; red). Scale bar represents 40 mm.
(B) Western blot analysis of protein lysates from Tg2576 mESC-derived neuronal culture harvested at the indicated DIV express APP, cleaved APP fragments
(APP-CTF), and the neuronal proteins S-physin, CamKIIa, and neuronal b-tubulin III (TUJ1). a-Actin is a loading control.
(C) Cell lysates from DIV 7 Tg2576 ESNs treated with the indicated compounds were subjected to western blot detection with 6E10 (APP-FL), APP-CTmax (APP-
CTF), and antibodies targeting indicated proteins.
(D) sAPPa and sAPPb were immunoprecipitated from conditioned medium after treatment of Tg2576 ESNs with the indicated compounds and detected using
western blot analysis with LN27.
(E and F) Secreted Ab levels were detected using a human-specific Ab40 or Ab42 ELISA kit. Ab40 and Ab42 show characteristic sensitivity to BSI and GSI in-
hibition. IC50 values for the BACE1 inhibitor were 229.7 nM and 28.1 nM for Ab40 and Ab42, respectively. IC50 values for compound E were 136.9 pM and 102.2
pM Ab40 and Ab42, respectively. The Z0 factors were 0.85 for Ab40 and 0.5 for Ab42, indicating an excellent assay for HTS.
See also Figure S2.
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Alzheimer’s Disease Neuronal Model from Stem Cellswindow, also indicated that the detection of Ab40 and Ab42 was
sufficiently higher than the variance of the assay (data not
shown).
Identification of Clinical Compounds that Reduce Ab
Secretion in ESNs
To fully validate the ESN-based assay, we screened for inhibitors
of Ab secretion using the NIH Clinical Collection (NCC), which
consists of 446 small molecules with a history of use in humans
(Noorbakhsh et al., 2009). Compounds were identified as hits if
they reduced Ab40 by 40% and deviated 4 SDs from the average
value of negative controls (Figure 6A) but maintained cell viability
within 2 SDs of control (Figure 6B). The most potent hits identi-
fied were amiridine, icariin, phenelzine, and progesterone (Fig-
ure 6C). We obtained the compounds from an independent
source, confirmed their activity, and subjected them to IC50Chemistry & Biology 20,determination (Figure 6D). To investigate the possible mecha-
nisms of the Ab-reducing activity of these compounds, we deter-
mined alterations in APP processing in response to compound
treatment. Icariin, phenelzine, and progesterone reduced sAPPb
levels, suggesting that these compounds may modulate the ac-
tivity of BACE1 (Figures 6E and 6F). None of the compounds
significantly affected the levels of sAPPa or full-length APP (Fig-
ures 6D, 6G, and 6H). Ab40 was confirmed to be reduced by the
hit compounds (Figure 6I).
Pharmacological Response of Hit Compounds in ESNs
and Cell Lines
An advantage of phenotypic screening in ESNs is that it
preserves the cellular context of physiological neurons better
than commonly used cell-based screening assays based on
transformed cell lines. Therefore, we determined the ability of956–967, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 961
Figure 5. Miniaturization and Optimization
of the 96-Well Platform for Mouse ESNs
(A) DIV 8 Tg2576 ESNs were plated at increasing
density in a 96-well plate and subjected to a cell
viability assay quantified in relative fluorescent
units (RFU).
(B and C) %CV (B) and Z0 (C) were calculated with
increasing numbers of wells. The minimum %CV
andmaximum Z0 were optimized at n = 5 wells at a
plating density of 1.5 3 105 cells/cm2 (arrows in B
and C).
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BACE1-expressing cell lines. Interestingly, icariin, phenelzine,
and progesterone did not significantly reduce Ab secretion in
any of the three alternate cell lines we tested, including Neuro2a
expressing APPsw, Chinese hamster ovary (CHO) expressing
APP and mutant PS1 (DE9), and SH-SY5Y cells expressing
BACE1 and APP (Figure 7). Amiridine reduced Ab secretion in
the SH-SY5Y cell line; however, Ab-reducing activity was not
observed in Neuro2a or CHO cell lines (Figure 7).
DISCUSSION
In this study, we have presented some practical applications of
mouse ESNs for AD and CNS drug-discovery research. ESNs
serve as an infinite source of neurons that functionally and
morphologically recapitulate pyramidal neurons as well as har-
bor the appropriate machinery for APP processing and synaptic
function. We show that ESNs can be cultured and assayed in a
platform suitable for drug screening. Using ESNs from the
Tg2576 mouse model of AD, we established and validated an
HTS platform for an Ab detection assay. We have provided ex-
amples of how this platform can be used to probe various key
biological and pathophysiological pathways in intact primary
neurons, such as analyses of alterations in synaptic function
and structure, and APP processing. Our ESN platform may
also be applicable to parallel detection of multiple b-amyloid
phenotypes described in this paper, in addition to other AD-
associated phenotypes such as tau-associated abnormalities.
Thus, to address the complex biological mechanisms underlying
AD, our model allows the investigation of druggable pathways or
networks in intact neurons (Noorbakhsh et al., 2009).
The mouse ESN model has appreciably enhanced suitability
for HTS compared with hESC- and hiPSC-derived neurons. In
general, much longer expansion and differentiation periods are
required for ESNs and iPSC-derived neurons, which typically
require 21+ days for differentiation and up to 5 weeks for matu-
ration in culture to display the desired phenotypes (Barker, 2012;
Dhara and Stice, 2008; Schwartz et al., 2008). Thus, mESCs and
mouse ESNs have an advantage over human systems in that
they can be easily expanded in a practical amount of time for
automation (Erceg et al., 2009; Kim et al., 2011; Nistor et al.,
2011). Furthermore, because it is difficult to obtain relatively ho-
mogeneous neuronal populations from human pluripotent cells,
our mouse ESN-based approach, which employs relatively ho-
mogeneous and reproducible neuronal cultures, is more suitable
for quantitative detection assays (Ebert and Svendsen, 2010;
Engle and Puppala, 2013; Han et al., 2011). Recently, hiPSCs962 Chemistry & Biology 20, 956–967, July 25, 2013 ª2013 Elsevier Lfrom AD patients were successfully differentiated into neurons
that displayed several expected phenotypes, including elevated
Ab (Israel et al., 2012; Yagi et al., 2011). However, hiPSC-derived
neurons from one sporadic AD patient lacked the Ab increase
altogether, highlighting the inherent variability among patient-
derived hiPSCs due to differences in genetic background com-
pounded by the inherent variability among clones from a single
patient (Choi and Tanzi, 2012; Israel et al., 2012; Ooi et al.,
2013). Further, since AD has a mixed etiology, it is challenging
to select the appropriate control lines for iPSCs given the vari-
ability in genetic background of each patient (Barker, 2012;
Choi and Tanzi, 2012). In contrast, mESC lines can be harvested
from the numerous existingmousemodels, giving rise to disease
models and near-clonal appropriate controls. Genetic and
epigenetic integrity in iPSCsmay be compromised by insertional
defects owing to the integration of ectopic transcription factors
(Han et al., 2011; Papp and Plath, 2011). Synapse loss, a critical
feature in AD that correlates with disease severity, was not
observed in recent studies of iPSCs from AD patients, perhaps
due to limited culture duration (Choi and Tanzi, 2012; Yagi
et al., 2011); however, mouse ESNs display robust synapse for-
mation as well as Ab-triggered synapse loss (Figure 2). Thus,
mouse ESNs uniquely provide both phenotypic relevance and
HTS adaptability. Although mouse ESNs are favorable for HTS,
human-derived ESNs and iPSC-derived neurons currently hold
high value for secondary confirmatory studies to determine com-
pound efficacy and toxicity in the human genetic background.
The four most potent hits identified in our screen are known
CNS drugs. Amiridine belongs to the class of drugs known as
aminopyridine acetylcholinesterase inhibitors, including tacrine,
and such drugs have been used in the clinic for the symptomatic
treatment of AD (Braginskaya et al., 2001; Yoshida and Suzuki,
1993). An interesting future investigation would be to determine
whether the Ab-lowering activity is a common property of all
aminopyridine compounds in this drug class, and whether this
activity potentially influences clinical variables. Phenelzine is a
monoamine oxidase inhibitor (MAOI), a class of drugs that
have been studied for potential clinical use in AD based on their
ability to promote neurotransmission and improve cognition
(Freedman et al., 1998; Mangoni et al., 1991; Sano et al., 1997;
Volz and Gleiter, 1998). We found that phenelzine reduced Ab
and sAPPb secretion, suggesting that this compound may
reduce Ab through the inhibition of BACE1 in neurons. In previ-
ous studies, derivatives of this class of drug were reported to
inhibit g-secretase activity and stimulate sAPPa production in
cell lines (Lee et al., 2010; Weinreb et al., 2009; Youdim et al.,
2003). Thus, it is conceivable that phenelzine conferstd All rights reserved
Figure 6. Screening the NCC for Ab Biogenesis
(A) DIV 7 Tg2576 ESNs plated in the 96-well plate platform were treated with compounds from the NCC for 24 hr. Ab40 was detected in conditioned media and is
shown as % control DMSO-treated wells. The negative control (Ctrl) was DMSO, positive Ctrl 1 was BACE inhibitor IV, and positive Ctrl 2 was compound E.
(B) The remaining cells were subjected to the cell viability assay CellQuanti Blue.
(C) Potent hits were obtained from an independent source and subjected to IC50 determination in the 96-well platform for Ab40 biogenesis (amiridine: 6.29 mm;
icariin: 1.412 mm; phenelzine: 0.2834 mm; progesterone: 0.1746 mM) as determined by Prism analysis log(inhibitor) versus normalized response curve fit with
baseline level of Ab40 subtracted.
(D) Chemical structures of hit compounds.
(E) Representative western blot analysis of APP processing was determined using immunoprecipitation of secreted fragments a and b from condition media. Full-
length APP was determined in protein lysate using western blot analysis with 6E10 antibody, and CTFs were detected using APP-CTmax antibody. Neuronal
b-tubulin was detected using TUJ1.
(F and G) Quantification of sAPPb and sAPPa.
(H) Full-length APP was quantified by ImageJ analysis and normalized to tubulin (TUJ1).
(I) Quantification of Ab40 after treatment with the indicated compounds normalized to the protein level. Shown are means and SEM (n = 3).
Chemistry & Biology
Alzheimer’s Disease Neuronal Model from Stem Cells
Chemistry & Biology 20, 956–967, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 963
Figure 7. Disparity in the Pharmacological Response of Hit Com-
pounds between Tg2576 ESNs and Cell Lines
Tg2576 ESNs, Neuro2a cells stably overexpressing APPsw (N2a-APPsw),
CHO cells stably overexpressing wild-type APP and PS1 with the DE9 muta-
tion (CHO-APPPS1), and SH-SY5Y cells stably overexpressing GFP-BACE1
and hemagglutinin (HA)-tagged wild-type APP (BGWT8) were plated in 96-well
plates and treated with hit compounds (10 mM) for 6 hr. The media were then
harvested and tested for Ab40 content, which was normalized to DMSO-
treated cells for each type (% control). Absolute values for control DMSO-
treated cells: Tg2576 ESNs, 129 ± 29.2 pg/ml; N2a-APPsw, 346 ± 50.7 pg/ml;
CHO-APPPS1, 62.5 ± .7 pg/ml; and BGWT8, 28.8 ± 6.4 pg/ml.
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both b- and g-secretase pathways, although the cellular target(s)
have not yet been identified. Icariin has been reported to reduce
Ab-induced synaptic and cellular deficits (Li et al., 2010; Zeng
et al., 2010) and ameliorate memory impairment in Ab-treated
rats and amousemodel of AD (Nie et al., 2010; Urano and Tohda,
2010). Icariin has also been reported to reduce the expression of
BACE1 (Nie et al., 2010). Consistent with its reported role in
BACE1 regulation, we found that icariin reduced secretion of
sAPPb, which may have contributed to the cognitive improve-
ments observed in previous mouse model studies. Lastly, our
screen identified progesterone as an Ab-reducing compound.
In previous in vivo studies, progesterone was shown to reduce
amyloid load and improve cognitive performance in AD mouse
models (Carroll et al., 2010; Frye and Walf, 2008). Since proges-
terone lowered sAPPb, Ab40, and Ab42 production in neurons, it
is conceivable that Ab-reducing activity may underlie the
observed rescue of pathological and behavioral changes in
mouse models of AD. Collectively, these findings suggest that
our approach could be useful for evaluating the potential of
known drugs for a new use in AD in the context of phenotypically
intact neurons, as well as screening for novel small molecules.
SIGNIFICANCE
Our current study describes practical applications ofmESC-
derived neurons (ESNs) for AD and CNS drug-discovery
research. Our studies indicate that ESNs could potentially
replace dissociated primary neuron cultures as a cell-based
model for investigation of neurobiology and pathobiology
relevant to AD. We also demonstrated that ESNs from the
Tg2576 mouse model of AD can be cultured and assayed
in a platform suitable for drug screening. Using this ESN-
based assay, we performed phenotypic screening assays964 Chemistry & Biology 20, 956–967, July 25, 2013 ª2013 Elsevier Land identified four interesting clinical compounds for which
Ab-modulating effects have not been previously reported in
primary neurons. There is a growing demand for preclinical
models that can reliably predict efficacy and safety prior to
clinical trials. This demand can be met by specialized dis-
ease-relevant cell types. For drug-discovery applications,
our system offers notable advantages over human-patient-
derived stem cells, which have limited expandability and
phenotypic variability. Thus, our model overcomes current
challenges related to phenotypic HTS assays in neurons,
bridging the gap between in vitro screening paradigms and
translational drug discovery, and has great potential to
lead to innovation in AD drug discovery by furnishing pyra-
midal neurons amenable to screening and functional evalu-
ation of compound efficacy and toxicity in stem cell-derived
primary neurons.
EXPERIMENTAL PROCEDURES
Directed Differentiation of mESCs into Pyramidal Neurons
mESCs were maintained for two passages on mouse embryonic fibroblast
(MEF) feeder cells in the presence of Leukemia Inhibitory Factor (LIF;Millipore).
For embryoid body (EB) formation,mESCswere deprived ofMEFs for two pas-
sages. EBswere grown in suspension for 8 days and in the presence of retinoic
acid (RA) for the last 4 days prior to plating as neurons. Optimized neuronal me-
dia containing N2 supplement (Invitrogen) was used for the first 2 days after
plating, and B27 (Invitrogen) supplemented media was used for the duration
of the culture. Details regarding the media composition and protocols are pro-
vided in Supplemental Experimental Procedures.
Analysis of Synaptic Proteins, Morphology, and Spine Density
After DIV 21, ESNs were treated for 24 hr with 200 nM Ab oligomer, which was
prepared as previously described (Dahlgren et al., 2002; McIntire et al., 2012),
and then fixed in 4% paraformaldehyde and 4% sucrose in PBS for 20 min.
PSD-95 (Thermo Scientific) and S-physin (Epitomics) antibodies were used
and detected with Alexa-tagged secondary antibodies (Molecular Probes).
For spine analysis, after fixation the neurons were labeled with DiI (Molecular
Probes) as previously described (Moolman et al., 2004; McIntire et al., 2012).
Images were collected with an inverted Olympus microscope with a 1003
objective using a Nikon C2 confocal laser microscope system. For spine anal-
ysis, 0.5 mM z sections were taken at 33 zoom. Images were stacked, used for
2D projection with ImageJ 1.4g software (NIH), and measured with the
Segmented Line tool. For particle analysis, the RGB colors were split, a
threshold was set for each image, and the Analyze Particles tool was used.
pCREB Detection
Neurons were grown to maturity and pretreated for 1 hr in the presence or
absence of the Ab oligomer preparation. Subsequently, cultures were treated
for 10 min under stimulating conditions (150 mM, 5 mM KCl, 2 mM CaCl2,
30 mM glucose, 10 mM HEPES, pH 7.4, 10 mM NMDA) (Snyder et al., 2005)
or nonstimulating conditions (120 mM NaCl, 3 mM KCl, 2 mM CaCl2, 2 mM
MgCl2, 15 mM glucose, 15 mM HEPES, pH 7.4) in the presence or absence
of Ab oligomer (Dahlgren et al., 2002). Protein was solubilized immediately in
Laemmli sample buffer and loaded (v/v) to 4%–20% Tris/glycine gel
(Invitrogen). Protein was separated by SDS-PAGE, and quantitative western
blotting was accomplished using infrared secondary antibody (Rockland)
detection with the Li-Cor Odyssey Infrared Imager with a solid-state diode
laser at 685 nm and 785 nm. Total CREB primary antibody was obtained
from Santa Cruz Biotechnology, and pCREB (S133) primary antibody was ob-
tained from Invitrogen.
Subcellular Fractionation
Differentiated mESCs were homogenized using a ball-bearing homogenizer in
homogenization buffer (0.25 M sucrose, 10 mM Tris, pH 7.4, 2 mMMgAC, and
0.5 mM EDTA, supplemented with protease inhibitors [Roche]). Thetd All rights reserved
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fuged for 2.5 hr at 39,000 rpm at 4C. Ten fractions were collected and
analyzed by western blotting. The primary antibodies used were anti-sortilin
(BD Biosciences), anti-BACE1 (Zhao et al., 2007), anti-APP-CTmax (Landman
et al., 2006; Okada et al., 2010), anti-syn6 (BD Biosciences), anti-EEA1 (Affinity
BioReagents), and anti-Rab11 (BD Biosciences).
Lentiviral Expression of APPsw in ESNs and Generation of FAD
Mutant PS1 Stable ESC Lines
Tomodel human APP processing, neurons were infected with APPsw lentivirus
for 24 hr. Then, 48 hr after initial infection, they were treated with BSI (Calbio-
chem) or GSI (Calbiochem) for 24 hr. Uninfected neurons were treated with
0.1% saponin (Sap) as a positive control for loss of cell viability. To generate
stable lines of mESCs expressing PS1 wild-type and FAD variants, 3 3 106
ESCs were resuspended in Nucleofector solution (Amaxa Neucleofector;
Lonza) and mixed with 20 mg plasmid carrying human wild-type or FADmutant
PS1 and neomycin resistance in the pcDNA3.1 vector. Cells were electropo-
rated using program A-13 (Amaxa), resuspended, plated on feeder cells,
and subjected to G418 (250–500 mg/ml) selection 24 hr after electroporation.
Analysis of APP Processing
At DIV 12–30, neurons were infected with lentivirus carrying the Swedish
variant of human APP (pLenti6/hAPPsw). After 24 hr, the cell medium was
changed, and 48 hr after infection, the cells were treated with secretase inhib-
itors. Conditioned media were collected after 24 hr and the levels of Ab42 and
Ab40 were determined using sandwich ELISA (Invitrogen) according to the
manufacturer’s protocol. Total protein levels were determined by BCA protein
assay (Pierce). Total Ab was detected by immunoprecipitating conditioned
medium with 6E10 (Covance) or 7N22 (Invitrogen) antibodies. Immunoprecip-
itates were then separated on NuPAGE gels and detected by quantitative
western blotting with 6E10 antibody. Full-length APPwas detected by western
blot analysis using 6E10 (Covance) or polyclonal antibody against the C termi-
nus of APP (APP-CTmax) (Landman et al., 2006; Okada et al., 2010). For detec-
tion of sAPPb and sAPPa, conditioned medium was harvested 24 hr after a
media change. Immunoprecipitation of sAPPbwas performed using sbsw anti-
body (Figure S2). Protein G plus/Protein A agarose suspension (Calbiochem)
was used to precipitate the antibody-protein complex. The immunoprecipitate
was subjected to SDS-PAGE followed by western blot detection using 22C11
(Chemicon) or LN27 (Covance). sAPPa was immunoprecipitated with 6E10
and detected on western blot with LN27. BACE inhibitor IV, compound E,
and TAPI-2 were obtained from Calbiochem.
Isolation of ESCs from a Mouse Model of AD
Tg2576 mice were an outbred strain of Swiss Webster 3 B6D2F1, which is a
C57BL/6 3 DBA/2 F1 cross harboring the APP transgene with the Swedish
mutation under the control of the prion promoter (Hsiao et al., 1996).
C57BL/6 females (23 days old) were induced for superovulation with a stan-
dard protocol using intraperitoneal injection with pregnant mare serum gonad-
otropin (PMSG) on day 1 and human chorionic gonadotropin (hCG) on day 3.
Immediately following the final injection, the female was mated with a male
positive for the APPsw transgene. After 3.5 days, blastocysts were flushed
from the uterus and cultured in 96-well feeder plates containing mitomycin
C-treated MEF feeders in ESC medium for 6 days without a medium change.
Inner cell mass (ICM) outgrowth was disaggregated with 0.05% trypsin into
small clumps and plated in one well of 24-well feeder plates. ESC colonies
were apparent on day 3 after replating, and ESCs were passaged upon conflu-
ence and maintained as above. DNA was isolated using the DNeasy and Tis-
sue DNA isolation kit (QIAGEN). ESC lines harboring the transgene were iden-
tified using a PCR-based genotyping protocol with primers against the human
APPsw gene sequence (sense primer 1: CCGAGATCTCTGAAGTGAAGATG
GATG; antisense primer 2: GTGGATACCCCCTCCCCCAGCCTAGACC).
Small-Molecule Screen of a Clinical Compound Library for
Reduction of Ab
ESNs were plated in 96-well black plates at a density of 1.5 3 105 cells/cm2
(45,000 cells/well). After DIV 8, the ESNswere treated with 10 mMof each com-
pound from a library of 446 clinically relevant compounds that have a history of
use in humans (NCC; NIH) for 24 hr in B27 media. Each plate of ESNs wasChemistry & Biology 20,treated additionally with DMSO (negative control) and positive controls for
Ab reduction (BSI and GSI) using six replicates. After 24 hr, the conditioned
media were harvested and frozen at80C until Ab40 analysis was performed
using a human-specific ELISA (Invitrogen). The remaining cells were subjected
to a cell viability assay (CellQuanti Blue; BioAssay Systems). Compounds were
considered hits if they reduced Ab40 by 40% compared with the negative con-
trol (DMSO) and reduced Ab40 by 4 SDs from the average value of the negative
control but maintained cell viability. Cell viability was defined by maintenance
of CellQuanti Blue fluorescent signal within 2 SDs of the control DMSO-treated
neurons. For confirmation studies, amiridine, phenelzine, and icariin were ob-
tained from Sigma, and progesterone was obtained from Tocris.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two figures and can be found with this article online at http://dx.doi.org/
10.1016/j.chembiol.2013.06.005.
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